Tarsus Pharmaceuticals (TARS) Shares Outstanding (Diluted Average) (2020 - 2026)
Tarsus Pharmaceuticals (TARS) recorded quarterly Shares Outstanding (Diluted Average) of $43.0 million in Q1 2026, up 2.81% quarter-over-quarter from $41.8 million in Q4 2025, and up 9.18% on a YoY basis from $39.3 million in Q1 2025.
Tarsus Pharmaceuticals (TARS) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $43.0 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 9.18% year-over-year to $43.0 million; the TTM figure through Mar 2026 stood at $43.0 million (up 9.18% YoY), while the FY2025 annual figure was $41.8 million, up 11.11% from the prior year.
- Shares Outstanding (Diluted Average) was $43.0 million for Q1 2026 at Tarsus Pharmaceuticals, up from $41.8 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $43.0 million in Q1 2026 to a low of $20.7 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $32.9 million across 5 years, with a median of $35.3 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) fell 5.11% in 2022, then soared 41.05% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $24.6 million in 2022, then grew by 19.35% to $29.4 million in 2023, then rose by 27.98% to $37.6 million in 2024, then rose by 11.11% to $41.8 million in 2025, then climbed by 2.81% to $43.0 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $43.0 million (Q1 2026), $41.8 million (Q4 2025), and $41.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Tarsus Pharmaceuticals | 2.71 Bn | 2.61 Bn | 152.66 Mn | 42.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.96 Mn |
| Dec 31, 2025 | 41.78 Mn |
| Sep 30, 2025 | 41.46 Mn |
| Jun 30, 2025 | 42.36 Mn |
| Mar 31, 2025 | 39.35 Mn |
| Dec 31, 2024 | 37.60 Mn |
| Sep 30, 2024 | 38.38 Mn |
| Jun 30, 2024 | 37.82 Mn |
| Mar 31, 2024 | 35.30 Mn |
| Dec 31, 2023 | 29.38 Mn |
| Sep 30, 2023 | 28.07 Mn |
| Jun 30, 2023 | 26.82 Mn |
| Mar 31, 2023 | 26.74 Mn |
| Dec 31, 2022 | 24.62 Mn |
| Sep 30, 2022 | 23.92 Mn |
| Jun 30, 2022 | 22.53 Mn |
| Mar 31, 2022 | 20.71 Mn |
| Dec 31, 2021 | 20.55 Mn |
| Sep 30, 2021 | 22.03 Mn |
| Jun 30, 2021 | 21.97 Mn |